Literature DB >> 17072624

Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.

Gunther Klautke1, Rainer Fietkau.   

Abstract

BACKGROUND: The rate of local recurrence of locally advanced rectal cancer (stage III and IV according to the criteria of Union Internationale Contre Le Cancer) is still high, and also the rate of distant metastases. There are a lot of phase I/II trails of intensified neoadjuvant radiochemotherapy with different chemotherapeutic agents and current protocols to radiotherapy. AIM: The objective of this review of literature was to evaluate the necessity, the results, and comparability of the different regimes and to evaluate a potential impact on later adjuvant chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17072624     DOI： 10.1007/s00384-006-0204-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN： 0179-1958            Impact factor:   2.571


  40 in total

1.  Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.

Authors:  R Trisolini; L Lazzari Agli; D Tassinari; D Rondelli; A Cancellieri; M Patelli; F Falcone; V Poletti
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

2.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

3.  Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

Authors:  J-P Machiels; L Duck; B Honhon; B Coster; J-C Coche; P Scalliet; Y Humblet; S Aydin; J Kerger; V Remouchamps; J-L Canon; P Van Maele; L Gilbeau; S Laurent; C Kirkove; M Octave-Prignot; J-F Baurain; A Kartheuser; C Sempoux
Journal:  Ann Oncol       Date:  2005-10-11       Impact factor: 32.976

4.  Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

Authors:  Christopher H Crane; Lee M Ellis; James L Abbruzzese; Christina Amos; Henry Q Xiong; Linus Ho; Douglas B Evans; Eric P Tamm; Chaan Ng; Peter W T Pisters; Chusilp Charnsangavej; Marc E Delclos; Michael O'Reilly; Jeffrey E Lee; Robert A Wolff
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

5.  Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur.

Authors:  F A Calvo; M Gómez-Espí; J A Díaz-González; R Cantalapiedra; P Marcos; A Alvarado; P García Alfonso; R Herranz; E Alvarez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-12-01       Impact factor: 7.038

6.  Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.

Authors:  J E Tepper; M J O'Connell; G R Petroni; D Hollis; E Cooke; A B Benson; B Cummings; L L Gunderson; J S Macdonald; J A Martenson
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

7.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

8.  Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.

Authors:  Ralf-Dieter Hofheinz; Bolko von Gerstenberg-Helldorf; Frederik Wenz; Ulrike Gnad; Uta Kraus-Tiefenbacher; Albrecht Müldner; Rüdiger Hehlmann; Stefan Post; Andreas Hochhaus; Frank Willeke
Journal:  J Clin Oncol       Date:  2005-01-31       Impact factor: 44.544

9.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.

Authors:  G Klautke; P Feyerherd; K Ludwig; F Prall; T Foitzik; R Fietkau
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640
View more
  5 in total

Review 1.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

Review 2.  [Concurrent radiochemotherapy for the treatment of solid tumors].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

3.  Locally advanced mid/low rectal cancer with synchronous liver metastases.

Authors:  Luca Viganò; Mehdi Karoui; Alessandro Ferrero; Claude Tayar; Daniel Cherqui; Lorenzo Capussotti
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

4.  Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.

Authors:  Ramon Salazar; Matilde Navarro; Ferran Losa; Vicente Alonso; Manel Gallén; Fernando Rivera; Manuel Benavides; Pilar Escudero; Encarnación González; Bartomeu Massutí; Auxiliadora Gómez; Margarita Majem; Enrique Aranda
Journal:  Clin Transl Oncol       Date:  2012-07-11       Impact factor: 3.405

5.  Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.

Authors:  Bengt Gustavsson; Göran Carlsson; Torbjörn Swartling; Göran Kurlberg; Kristoffer Derwinger; Hillevi Björkqvist; Elisabeth Odin; Fernando Gibson
Journal:  Invest New Drugs       Date:  2015-07-21       Impact factor: 3.850
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.